Navigation Links
Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
Date:1/24/2013

Albany, New York (PRWEB) January 24, 2013

In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018.

The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.

Related Report :Theranostics Market
http://www.transparencymarketresearch.com/theranostics-market.html

Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.

The major players in the liver diseases therapeutics market include Astellas Pharma Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. In 2011, Astellas was the market leader in the immunosuppressants drugs market for liver diseases followed by Pfizer. In liver disease vaccines market, GlaxoSmithKline Pharmaceuticals Limited (GSK) represented as the major market player with a share of 45% in 2011. Bristol Myers Squibb had the largest market share in anti-viral drugs market for liver diseases followed by Gilead science in 2011.

Related Report :Nano-Biotechnology Market
http://www.transparencymarketresearch.com/nano-biotechnology-market.html

This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.

Visit: http://www.transparencymarketresearch.com/

Read the full story at http://www.prweb.com/releases/2013/1/prweb10347536.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
2. CT Scans Deliver More Radiation to Obese People: Study
3. Modest alcohol consumption lowers risk and severity of liver disease
4. Childhood Obesity May Raise Odds of Adult Liver Cancer
5. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
6. Combination of 2 drugs reverses liver tumors
7. New guidelines deliver concise messages for implementing cardiovascular prevention
8. Liver fat gets a wake-up call that maintains blood sugar levels
9. Hepatitis C Causing Liver Damage in Greater Numbers: Study
10. Body Building, Diet Supplements Linked to Liver Damage: Study
11. U.S. Liver Transplants Declining
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Fire Door Solutions, headquartered ... the Fire Door Solutions’ team. Keith will serve Fire Door Solutions as ... re-labeling. He will be instrumental in developing educational curriculum and leading training ...
(Date:5/31/2016)... ... 31, 2016 , ... Throughout the day, adults often find themselves reaching for a cup of ... they could be reaching for instead is a cup of Matcha green tea. Matcha is ... This sacred tea is harvested from early June to mid-July, when the leaves are the ...
(Date:5/31/2016)... Atlanta, GA (PRWEB) , ... May 31, 2016 ... ... Contact Center Solutions , today announced it has been included by Gartner, ... 2016 report mentions a wide range of Contact Center Infrastructure technologies, some of ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two hospital ... patients from other participating organizations in the exchange. SJMC’s membership in the health ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... using a mix of advanced Artificial Intelligence (AI) and the latest in ... The medical center is integrating predictive analytic outputs directly into the clinical workflow. ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
Breaking Medicine Technology: